XTL Biopharmaceuticals Company Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel.

Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome.

It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.

The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.

XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

XTL Biopharmaceuticals Ltd.

Country	Israel
Founded	1993
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Shlomo Shalev

Contact Details

Address: 26 Ben-Gurion St. Ramat Gan, 5112001 Israel
Phone	972 3 611 6600
Website	xtlbio.com

Stock Details

Ticker Symbol	XTLB
Exchange	Tel Aviv Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	IL0010854979
SIC Code	2836

Key Executives

Name	Position
Shlomo Spokone Shalev	Chief Executive Officer and Director
Itay Weinstein	Chief Financial Officer